Defense Health Agency Contracting Activity - DHACA
· Federal agency
DoD Ovarian Cancer, Omics Consortium Development Award
The FY18 OCRP Omics Consortium Development Award supports a multi-institutional research effort conducted by leading ovarian cancer researchers and consumer advocates that specifically focuses on the compilation of new a...
84
match
Deadline2874 days agoLocationAlabamaTypegrantLevelFederalClosedposted Apr 11, 2018
✦ AI Summary
Who can apply: Federal-level applicants (see eligibility for details).
Funding amount: total funding pool ~$1,920,000.
Next deadline: August 8, 2018.
Issued by: Defense Health Agency Contracting Activity - DHACA.
The “key facts” mode pulls structured fields directly from the official source posting (amount, deadline, eligibility tags). The AI mode adds a short plain-English narrative on top, generated from the same source. Always verify with the agency before applying.
AI-generated. Always verify with the official source.
Deadline
2874 days ago
Aug 8, 2018
Total pool
$1.9M
About this opportunity
The FY18 OCRP Omics Consortium Development Award supports a multi-institutional research effort conducted by leading ovarian cancer researchers and consumer advocates that specifically focuses on the compilation of new and/or use of existing large datasets to study the origin of ovarian cancer disease with an emphasis on early detection and screening. This effort will be executed through a two-stage approach using two separate award mechanisms: the first is the current funding opportunity, the FY18 Omics Consortium Development Award, which will enable the consortium to lay the groundwork for the research project, including a proof of concept preliminary research project; and the second is an FY20 Omics Consortium Award, which will support the execution of the full research project. Research projects proposed under the Omics Consortium Development Award must use large datasets (genomics, ‘omics) to focus on origin of disease. The long-term goal of the Omics Consortium is to facilitate improvements in early detection and screening of ovarian cancer, although immediate benefits of the consortium will be in initial diagnosis and therapy. With this in mind, applicants are encouraged to include rare subsets and putative pre-malignant lesions, as well as linkage to relevant interventional clinical trials, to be included in the data gathered by the Omics Consortium Development Award. Applications for the first stage, the Omics Consortium Development Award, are being requested in this funding opportunity. The Omics Consortium Development Award provides support to: • Develop the infrastructure of the consortium ( building appropriate collaborations, outlining an administrative and management plan, developing a research and communication plan, and devising an intellectual property plan) and a multi-institutional research team inclusive of ovarian cancer consumer advocates; • Acquire research resources; • Develop a plan to disseminate information regarding the procurement and distribution of data and/or biospecimens to the non-consortium ovarian cancer research community; • Develop a detailed statistical plan with refined power analysis; • Conduct a preliminary research project to demonstrate proof of concept; • Prepare documents for obtaining approvals from local Institutional Review and • Develop informed consent forms, as applicable. The Principal Investigator (PI), as the Consortium Director, is expected to have experience in successfully leading the management of multi-institutional research projects. The PI should create an environment that fosters and supports innovation and creativity, with consistent, intensive interaction within the research team in a way that engages all members of the consortium in all aspects of the research project. Research sites in this consortium should be scientists and/or clinicians who have made significant contributions to the field of ovarian cancer or who have specific expertise related to the research project. This award is meant to facilitate new collaborations. If support for a pre-existing consortium is proposed, then evidence of new collaborations must be apparent within the application. The research team must include (1) at least one Early-Career Investigator who is within 5 years of his/her last postdoctoral research position clinical fellowship or equivalent, (2) at least one ovarian cancer consumer advocate, and (3) at least one Epidemiologist/Public Health Expert, all of whom should be integrally involved throughout the planning and implementation of the research project. As lay representatives, the consumer advocates must be individuals who have been diagnosed with ovarian cancer and who belong to an ovarian cancer advocacy organization. They must have a high level of familiarity and training involving current issues in ovarian cancer research, or a plan for such training should be included in the proposal.
Read the agency's eligibility checklist before you start — it's almost always shorter than the full NOFO and will tell you in 90 seconds whether to keep going.
Need help getting in touch with the right agency contact?
Create a free account and our specialists will guide you through the application end-to-end.